Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H14N4O5S |
| Molecular Weight | 314.318 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+]1=NN(C[C@@]2(C)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C([O-])=O)C=C1
InChI
InChIKey=HFZITXBUTWITPT-YWVKMMECSA-N
InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
| Molecular Formula | C11H14N4O5S |
| Molecular Weight | 314.318 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:02:21 GMT 2025
by
admin
on
Tue Apr 01 17:02:21 GMT 2025
|
| Record UNII |
80VUN7L00C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C171696
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY | |||
|
23653540
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY | |||
|
300000010200
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY | |||
|
80VUN7L00C
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY | |||
|
1001404-83-6
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY | |||
|
MN-141
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY | |||
|
10913
Created by
admin on Tue Apr 01 17:02:21 GMT 2025 , Edited by admin on Tue Apr 01 17:02:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum .BETA.-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to 3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs. Addition of AAI101 restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms.
|
